BioCryst Pharmaceuticals (NASDAQ:BCRX) is one of today's best performing low-priced stocks, up 25.0% to $2.00 on 4.3x average daily volume. BioCryst Pharmaceuticals has traded 2.9 million shares thus far today, vs. average volume of 676,000 shares per day. The stock has outperformed the Dow (25.0% to the Dow's 0.0%) and outperformed the S&P 500 (25.0% to the S&P's -0.1%) during today's trading.

BioCryst Pharmaceuticals, Inc., a biopharmaceutical company, discovers and designs novel small-molecule pharmaceuticals using structure-based drug design. The Company's products are used for the treatment of immunological, viral, and cardiovascular diseases and disorders. BioCryst's lead immunological drug program targets T-cell proliferative disorders.

In the past 52 weeks, BioCryst Pharmaceuticals share prices have been bracketed by a low of $1.08 and a high of $5.95 and are now at $2.00, 85% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.1% while the 200-day MA has remained constant.

BioCryst Pharmaceuticals has overhead space with shares priced $2.00, or 40.0% below the average consensus analyst price target of $3.33. BioCryst Pharmaceuticals shares should first meet resistance at the 200-day moving average (MA) of $4.08 and find additional resistance at the 50-day MA of $4.09.

SmarTrend is monitoring the recent change of momentum in BioCryst Pharmaceuticals. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of BioCryst Pharmaceuticals in search of a potential trend change.